Market Cap
$412.2M
MYGN
MYRIAD GENETICS INC
$4.54 ▲ +11.82%
Prev close $4.06Market cap$412.2M
ConsensusStrong Sell
12-mo target$3.91 (-13.8%)
▼ Bearish
Analyst conviction 1/10
Insider Buying Cluster (2 insiders)High Impact Filing (7/10)23 New Institutional Positions19 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on MYGN right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Sell (13%)
Inst. Holders
50 funds
Inst. Value
$425.2M
Inst. Activity
23 buys / 19 sells
Insider Activity
$27.6K buy / $66.8K sell
Insider Net $
-$39.2K
SEC Reports
5
Press Releases
3
Price chart 30d +40.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 21, 2026 Insider
Sep 16, 2026 SEC Wheeler Benjamin Richard surrendered for taxes 2,555 shares
Chief Financial Officer @ $4.01 ($10.2K)
Myriad Genetics announced the departure of Chief Commercial Officer Brian Donnelly (effective Sept 16, 2026, with a tran
8-K — Impact 3/10
Myriad Genetics announced the promotion of Vishal Sikri to EVP-Commercial, replacing departing CCO Brian Donnelly. The c
Impact 3/10
Sep 16, 2026 leadership
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Sep 16, 2026 Insider
Sikri Vishal was granted 257,731 shares
EVP, Commercial
Sep 3, 2026 Insider
Aug 4, 2026 SEC Fox Jennifer Lynne surrendered for taxes 4,398 shares
Chief Legal Officer @ $3.23 ($14.2K)
Myriad Genetics' Q2 2026 EPS of -$0.25 missed consensus of -$0.07 by 263.6%, while revenue of $203.8M was in line. The c
PRESS-RELEASE — Impact 7/10
Myriad Genetics reported Q2 2026 revenue of $190.7M (11% YoY decline, 7.4% below consensus) and adjusted EPS of -$0.25 (
PRESS-RELEASE — Impact 7/10
Analyst ratings buy % -23.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
13% rate it Buy or better · 15 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 2, 2026 | Craig-Hallum | MAINTAIN | Buy | 54% |
| Sep 9, 2026 | UBS | MAINTAIN | Neutral | 55% |
| Sep 1, 2026 | Piper Sandler | DOWNGRADE | Underweight | 54% |
| Aug 18, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight | 54% |
| Aug 3, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Jul 31, 2026 | TD Cowen | MAINTAIN | Hold | 56% |
| May 6, 2026 | TD Cowen | MAINTAIN | Hold | 56% |
| May 6, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 0 | 2 | 8 | 2 | 3 | 13% | |
| Aug 1, 2026 | 0 | 2 | 8 | 2 | 3 | 13% | |
| Jul 1, 2026 | 0 | 2 | 8 | 2 | 3 | 13% | |
| Jun 1, 2026 | 0 | 2 | 9 | 2 | 3 | 13% | |
| May 1, 2026 | 0 | 2 | 9 | 3 | 3 | 12% | |
| Apr 1, 2026 | 0 | 3 | 9 | 3 | 3 | 17% | |
| Mar 1, 2026 | 0 | 3 | 9 | 3 | 3 | 17% | |
| Feb 1, 2026 | 0 | 3 | 9 | 3 | 3 | 17% |
Price targets
Where 8 covering analysts think MYGN trades over the next 12 months.
$3.91 -13.8% upside Sell
Current$4.54 Low$2.00 Median$3.40 High$8.00 8 analysts
$2.00$8.00
Analyst rating Hold· 3.2/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 1 bullish, 2 bearish, 0 mixed, 2 neutral · avg impact 5.2/10.Plus 3 press releases.
NEUTRAL8-K3/10
Myriad Genetics announced the departure of Chief Commercial Officer Brian Donnelly (effective Sept 1
Sep 16, 2026
BEARISHPRESS-RELEASE7/10
Myriad Genetics' Q2 2026 EPS of -$0.25 missed consensus of -$0.07 by 263.6%, while revenue of $203.8
Aug 4, 2026
BEARISHPRESS-RELEASE7/10
Myriad Genetics reported Q2 2026 revenue of $190.7M (11% YoY decline, 7.4% below consensus) and adju
Jul 30, 2026
BULLISHINST-CLUSTER6/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased th
Feb 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 16, 2026
leadership
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Sep 10, 2026
short_volume
Short Volume: MYGN — 74.1% short (1.6M / 2.1M)
Short: 1,585,039 | Exempt: 5 | TRF Vol: 2,138,433 | Short Ratio: 74.1% | Off-exchange volume (dark pool + OTC)
Sep 1, 2026
short_volume
Short Volume: MYGN — 59.6% short (0.7M / 1.2M)
Short: 700,270 | Exempt: 0 | TRF Vol: 1,175,650 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
Aug 27, 2026
other
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
Myriad Genetics will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST.
Aug 13, 2026
short_volume
Short Volume: MYGN — 56.3% short (0.4M / 0.6M)
Short: 361,210 | Exempt: 0 | TRF Vol: 641,955 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.20 | $-0.27–$-0.15 | 0.0% | +6.7% | 0↑ 8↓ | $0.2B | 8 |
| Next Q | $-0.18 | $-0.24–$-0.09 | -555.1% | +6.7% | 0↑ 8↓ | $0.2B | 8 |
| Current FY | $-0.74 | $-0.89–$-0.58 | -1331.8% | +3.0% | 0↑ 9↓ | $0.8B | 9 |
| Next FY | $-0.58 | $-0.76–$-0.46 | 21.2% | +0.3% | 0↑ 5↓ | $0.8B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.198 | — |
| 7d ago | $-0.207 | +0.009 |
| 30d ago | $-0.212 | +0.014 |
| 60d ago | $-0.162 | -0.036 |
| 90d ago | $0.071 | -0.269 |
Institutional ownership
Which big funds own MYGN (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $425.2M total value (74,468,225 shares) as of 2026-Q2. Top holders: BlackRock,, MILLENNIUM, STATE. Net buying activity: 23 institutions added/increased vs 19 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 10,890,440 | $62.2M | 14.6% | TRIM -41.9% |
| MILLENNIUM MANAGEMENT LLC | 6,620,372 | $37.8M | 8.9% | — |
| STATE STREET CORP | 4,985,060 | $28.5M | 6.7% | TRIM -25.9% |
| D. E. Shaw & Co., Inc. | 4,582,083 | $26.2M | 6.2% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,081,376 | $23.3M | 5.5% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3,079,670 | $17.6M | 4.1% | — |
| AQR CAPITAL MANAGEMENT LLC | 2,766,689 | $15.8M | 3.7% | — |
| MORGAN STANLEY | 2,481,104 | $14.2M | 3.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,416,197 | $13.8M | 3.2% | — |
| GOLDMAN SACHS GROUP INC | 2,056,843 | $11.7M | 2.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Nuveen, LLC | ADD | 918,963 | 1,545,549 | +68.2% | $8.8M |
| CITADEL ADVISORS LLC | DOUBLED | 453,042 | 1,533,684 | +238.5% | $8.8M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 739,051 | 1,051,996 | +42.3% | $6.0M |
| Assenagon Asset Management S.A. | TRIM | 1,446,961 | 1,031,464 | -28.7% | $5.9M |
| Man Group plc | DOUBLED | 278,202 | 908,733 | +226.6% | $5.2M |
| BANK OF AMERICA CORP /DE/ | ADD | 523,020 | 901,896 | +72.4% | $5.1M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | 204,608 | 782,765 | +282.6% | $4.5M |
| FMR LLC | ADD | 585,277 | 772,217 | +31.9% | $4.4M |
| PRUDENTIAL FINANCIAL INC | ADD | 381,123 | 617,063 | +61.9% | $3.5M |
| OP Asset Management Ltd | DOUBLED | 148,929 | 449,617 | +201.9% | $2.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
18 insiders, 50 transactions. Net -$39.2K — $27.6K bought, $66.8K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | Wheeler Benjamin Richard | Chief Financial Officer | TAX W/H | 2,555 | $4.01 | $10.2K |
| Sep 16, 2026 | Sikri Vishal | EVP, Commercial | AWARD | 257,731 | — | — |
| Sep 3, 2026 | Fox Jennifer Lynne | Chief Legal Officer | TAX W/H | 4,398 | $3.23 | $14.2K |
| Aug 16, 2026 | Wheeler Benjamin Richard | Chief Financial Officer | TAX W/H | 8,761 | $3.03 | $26.5K |
| Jun 11, 2026 | Donnelly Brian J | Chief Commerical Officer | AWARD | 5,000 | $3.94 | $19.7K |
| Jun 11, 2026 | Raha Samraat S. | President and CEO | AWARD | 3,542 | $3.94 | $13.9K |
| Jun 8, 2026 | Kumar Rashmi | Director | SELL | 15,000 | $4.46 | $66.8K |
| Jun 4, 2026 | Dreismann Heinrich | Director | AWARD | 59,701 | — | — |
| Jun 4, 2026 | Reitan Colleen F | Director | AWARD | 59,701 | — | — |
| Jun 4, 2026 | Bisaro Paul | Director | AWARD | 59,701 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MYGN.
Shares short
9,345,601
Settlement Sep 15, 2026
Change vs prior
+19.1%
Semi-monthly cycle
Days to cover
4.3
At avg daily volume
Of shares outstanding
≈9.8%
Estimate — not % of float
All MYGN filing & press-release reports (8)
- 8-K reportSep 16, 2026
- PRESS-RELEASE reportSep 16, 2026
- PRESS-RELEASE reportAug 4, 2026
- PRESS-RELEASE reportJul 30, 2026
- PRESS-RELEASE reportMay 27, 2026
- PRESS-RELEASE reportMar 17, 2026
- INST-CLUSTER reportFeb 28, 2026
- S-3 reportFeb 24, 2026